Toshiba to market Elekta's products and clinical solutions in Japanese radiotherapy market

“This agreement is important in a country where cancer has become the leading cause of death”

Elekta K.K., a wholly owned subsidiary of Elekta AB (STO:EKTAB), has entered into a sales and marketing agreement with Toshiba Medical Systems Corporation in Japan.

According to the agreement, Toshiba Medical Systems Corporation will sell and market Elekta's products and clinical solutions in the Japanese radiotherapy market. This will ensure that patients there get unparalleled cancer care through Elekta's leading products and services.

Tim Rooney, President and Managing Director of Elekta K.K. says: "I am very pleased that we have entered into this important agreement with Toshiba Medical Systems Corporation. As a world leader in diagnostic imaging systems, coupled with its comprehensive sales network of 70 offices in Japan and extensive experience in the radiotherapy market, Toshiba Medical Systems Corporation is the perfect long-term partner for Elekta K.K. This collaboration will enable both companies to extend and enhance their commitment to providing world class, cutting-edge solutions to the Japanese radiotherapy market."

Yasuo Nobuta, Vice President of Toshiba Medical Systems Corporation, says the company is very pleased with the agreement with Elekta K.K.

"All of us at Toshiba Medical Systems Corporation are very excited about this agreement with Elekta K.K. as it will allow us to offer the most advanced forms of radiotherapy treatment to our customers and their patients in Japan" says Yasuo Nobuta.

Elekta K.K will manage the overall relationship with Toshiba Medical Systems Corporation through its sales, marketing and service organizations. Elekta K.K. expects the agreement to increase sales opportunities in Japan.

Growing need for cancer management resources "This agreement is important in a country where cancer has become the leading cause of death," Rooney says. "By opening up an additional sales channel for our linear accelerators and software products, we anticipate more people will get the quality of treatment they need."

According to statistics compiled by the Japanese Ministry of Health, Labour and Welfare, 336,290 people died of cancer in 2007; the disease was responsible for one out of every three deaths.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Elekta. (2023, September 12). Toshiba to market Elekta's products and clinical solutions in Japanese radiotherapy market. News-Medical. Retrieved on April 23, 2024 from https://www.news-medical.net/news/20101210/Toshiba-to-market-Elektas-products-and-clinical-solutions-in-Japanese-radiotherapy-market.aspx.

  • MLA

    Elekta. "Toshiba to market Elekta's products and clinical solutions in Japanese radiotherapy market". News-Medical. 23 April 2024. <https://www.news-medical.net/news/20101210/Toshiba-to-market-Elektas-products-and-clinical-solutions-in-Japanese-radiotherapy-market.aspx>.

  • Chicago

    Elekta. "Toshiba to market Elekta's products and clinical solutions in Japanese radiotherapy market". News-Medical. https://www.news-medical.net/news/20101210/Toshiba-to-market-Elektas-products-and-clinical-solutions-in-Japanese-radiotherapy-market.aspx. (accessed April 23, 2024).

  • Harvard

    Elekta. 2023. Toshiba to market Elekta's products and clinical solutions in Japanese radiotherapy market. News-Medical, viewed 23 April 2024, https://www.news-medical.net/news/20101210/Toshiba-to-market-Elektas-products-and-clinical-solutions-in-Japanese-radiotherapy-market.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Brainlab unveils ExacTrac Dynamic at ASTRO meeting in San Antonio, Texas